Shilpa Pharma Lifesciences Earns Top Marks In Global Quality Audit By ANVISA-Brazil
Shilpa Pharma Lifesciences gets GMP certification from ANVISA-Brazil for Raichur facility.
Shilpa Medicare Limited's subsidiary, Shilpa Pharma Lifesciences Limited, located at Raichur in Karnataka, has recently undergone a GMP inspection by ANVISA-Brazil from April 15 to April 19, 2024. Following a successful inspection, the facility has been awarded GMP Certification by ANVISA-Brazil. Specializing in manufacturing oncology and non-oncology APIs, the unit maintains a steadfast commitment to upholding GMP standards and quality norms set by Global Regulatory Authorities.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →Hepion Pharmaceuticals Gains FDA Clarity on GV104 Pathway for Gambling Disorder
FDA Pediatric Advisory Committee Releases September 2026 Meeting Materials for Biologics Review
Discussion